Communiqués Oragenics, Inc.

Actions

OGEN

US6840236094

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 15:30:11 14/08/2026			Varia. 5j.	Varia. 1 janv.
0,5350 ^USD	+0,92%		-2,47%	-32,32%

13/08	Oragenics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
07/07	Oragenics finalise l'activation de son réseau d'essais de phase IIa en Australie pour l'ONP-002 et progresse sur le plan réglementaire aux États-Unis	CI

Communiqués

13/08	Oragenics: Q2 Earnings Snapshot	AQ
07/07	Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling	AQ
20/05	Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21	AQ
19/05	Oragenics : Investor Presentation - May 2026	PU
19/05	Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21	AQ
18/05	ORAGENICS PROVIDES INVESTOR UPDATE	AQ
08/05	Oragenics: Q1 Earnings Snapshot	AQ
07/05	Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation	AQ
05/05	Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.	AQ
20/04	Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury	AQ
13/04	Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury	AQ
25/03	Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation	AQ
17/03	ORAGENICS FILES ANNUAL REPORT ON FORM 10-K	AQ
12/03	ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION	AQ
11/03	ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION	AQ
10/03	Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia	AQ
10/02	Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy	AQ
03/02	Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program	AQ
02/02	Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care	AQ
26/01	Oragenics : Investor Presentation - January 2026	PU
14/01	Oragenics to Present at the 2026 Sequire Investor Summit in Puerto Rico	AQ
12/11	Oragenics Q3 2025 Shareholder Update	BU
07/11	Oragenics: Q3 Earnings Snapshot	AQ
21/10/25	Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency	BU
07/10/25	Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development	BU